Leukemia Research Studies

< Back to Pediatric Cancer Research Studies Page

AML New Diagnosis

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

  • Ages: 12 years and older

The purpose of this study is to assess the safety and efficacy of oral administration of itacitinib once daily for the prevention of cytokine release syndrome (CRS) in male or female participants aged 12 years or older and who are planning to receive tisagenlecleucel or axicabtagene ciloleucel immun ...More

AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

  • Ages: From 3 to 36 months old

PURPOSE: This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killin ...More

AAML1831: A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Ages: up to 22 Years (Child, Adult) 

This phase III trial compares standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to ...More

Venetoclax Combined with Vyxeos for Relapsed/Refractory Acute Leukemia

  • Ages: 1 Year to 39 Years

This study evaluates the safety and tolerability of combining venetoclax with Vyxeos (CPX-351) in pediatric and young adult patients with acute leukemia that has come back or no responded to treatment. This is a single-institution Phase I pilot study designed to test the safety and tolerability of c ...More

Contact Us

Contact us.

To learn more about available leukemia clinical trials, contact us at cancer@cchmc.org or 513-636-2799.